Your browser doesn't support javascript.
loading
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Dimitrakopoulos, Foteinos-Ioannis; Goussia, Anna; Koliou, Georgia-Angeliki; Dadouli, Katerina; Batistatou, Anna; Kourea, Helen P; Bobos, Mattheos; Arapantoni-Dadioti, Petroula; Tzaida, Olympia; Koletsa, Triantafyllia; Chrisafi, Sofia; Sotiropoulou, Maria; Papoudou-Bai, Alexandra; Nicolaou, Irene; Charchanti, Antonia; Mauri, Davide; Aravantinos, Gerasimos; Binas, Ioannis; Res, Eleni; Psyrri, Amanda; Pectasides, Dimitrios; Bafaloukos, Dimitrios; Koumarianou, Anna; Bompolaki, Iliada; Rigakos, Georgios; Karanikiotis, Charisios; Koutras, Angelos; Zagouri, Flora; Gogas, Helen; Fountzilas, George.
Afiliación
  • Dimitrakopoulos FI; Division of Oncology, University Hospital of Patras "Panagia the Help", University of Patras, Patras, Greece; Molecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece. Electronic address: fodimitrakopoulos@upatras.gr.
  • Goussia A; Department of Pathology, Ioannina University Hospital, Ioannina, Greece; Department of Pathology, German Oncology Center, Limassol, Cyprus.
  • Koliou GA; Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.
  • Dadouli K; Laboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
  • Batistatou A; Department of Pathology, Ioannina University Hospital, Ioannina, Greece.
  • Kourea HP; Department of Pathology, University Hospital of Patras, Rion, Greece.
  • Bobos M; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, Thessaloniki, Greece.
  • Arapantoni-Dadioti P; Department of Pathology, Henry Dunant Hospital, Athens, Greece.
  • Tzaida O; Department of Pathology, Metaxas Cancer Hospital, Piraeus, Greece.
  • Koletsa T; Department of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
  • Chrisafi S; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Sotiropoulou M; Department of Pathology, Alexandra Hospital, Athens, Greece.
  • Papoudou-Bai A; Department of Pathology, Ioannina University Hospital, Ioannina, Greece.
  • Nicolaou I; Department of Histopathology, Agii Anargiri Hospital, Athens, Greece.
  • Charchanti A; Department of Anatomy-Histology-Embryology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
  • Mauri D; Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece.
  • Aravantinos G; Second Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
  • Binas I; Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
  • Res E; Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
  • Psyrri A; Section of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, Faculty of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  • Pectasides D; Oncology Section, Second Department of Internal Medicine, Hippokratio Hospital, Athens, Greece.
  • Bafaloukos D; First Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
  • Koumarianou A; Hematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Greece.
  • Bompolaki I; Oncology Department, General Hospital of Chania, Crete, Greece.
  • Rigakos G; Third Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
  • Karanikiotis C; Department of Medical Oncology, 424 Army General Hospital, Thessaloniki, Greece.
  • Koutras A; Division of Oncology, University Hospital of Patras "Panagia the Help", University of Patras, Patras, Greece.
  • Zagouri F; Department of Clinical Therapeutics, Alexandra Hospital, National Andistrian U Kapodniversity of Athens School of Medicine, Athens, Greece.
  • Gogas H; First Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  • Fountzilas G; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece; Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Medical Oncology, German Oncology Center, Limassol, Cyprus.
Breast ; 73: 103668, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38176305
ABSTRACT

BACKGROUND:

Dose-dense sequential (dds) chemotherapy has changed the clinical outcome of patients with early breast cancer (BC). To investigate the impact of dose intensity (DI) in the adjuvant setting of BC, this observational trial (HE 10/10) was conducted assessing the long-term survival outcome, safety and toxicity of a currently widely used chemotherapeutic regimen. In addition, the prognostic significance of tumor infiltrating lymphocytes (TILs) and infiltrating CD8+ lymphocytes were also evaluated in the same cohort. PATIENTS AND

METHODS:

Totally, 1054 patients were prospectively enrolled in the current study with 1024 patients being eligible, while adequate tissue was available for 596 of them. TILs, CD8+ lymphocytes in intratumoral areas in contact with malignant cells (iCD8), CD8+ lymphocytes in tumor stroma (sCD8) as well as the total number of CD8+ lymphocytes within the tumor area (total CD8) were assessed by immunohistochemistry.

RESULTS:

Within a median follow-up of 125.18 months, a total of 200 disease-free survival (DFS) events (19.5%) were reported. Importantly, the 10-year DFS and OS rates were 78.4% (95% CI 75.0-81.5) and 81.7% (95% CI 79.0-84.1), respectively. Interestingly, higher CD8+ T cells as well as TILs in the tumor microenvironment were associated with an improved long-term survival outcome.

CONCLUSIONS:

In conclusion, this study confirms the significance of dds adjuvant chemotherapeutic regimen in terms of long-term survival outcome, safety and toxicity as well as the prognostic significance of TILs and infiltrating CD8+ lymphocytes in BC patients with early-stage disease.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Observational_studies Límite: Female / Humans Idioma: En Revista: Breast Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Observational_studies Límite: Female / Humans Idioma: En Revista: Breast Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos